Tarrant County Public Health

17P Initiative

A program for prematurity prevention

17-Hydroxyprogesterone Caproate Benefit to Be Updated for Texas Medicaid Effective February 1, 2013

Information posted January 25, 2013

Effective for dates of service on or after February 1, 2013, 17-hydroxyprogesterone caproate benefit criteria will be updated for Texas Medicaid.

17-hydroxyprogesterone caproate is administered intramuscularly at a dose of 250 mg once a week (every 7 days) and is indicated when all of the following criteria are met:

- The client's treatment is initiated between 16 weeks, 0 days and 20 weeks, 6 days gestation.
- The client's treatment may continue, as medically indicated, through 36 weeks, 6 days gestation or delivery, whichever occurs first.
- The client has a singleton pregnancy.
- The client has had a prior, singleton, spontaneous, preterm delivery before 37 weeks gestation.

Use of a trademarked version of 17-hydroxyprogesterone caproate for injection (such as *Makena*), which must be prior authorized, will be indicated if one of the following additional criteria is met:

- The provider lacks access to the compounded product.
- Compounded 17-hydroxyprogesterone caproate for injection is contraindicated, for example, because of allergy to the compounded product.
- The Medical Director reviews supporting documentation and finds that trademarked 17-hydroxyprogesterone caproate for injection is medically necessary.

For more information, call the TMHP Contact Center at 1-800-925-9126.